<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437253</url>
  </required_header>
  <id_info>
    <org_study_id>30535</org_study_id>
    <nct_id>NCT02437253</nct_id>
  </id_info>
  <brief_title>Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI</brief_title>
  <official_title>Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect preliminary data on whether the drug adalimumab (also&#xD;
      called Humira) can decrease pain and stiffness, improve quality of life, and is safe in&#xD;
      people with mucopolysaccharidosis type I, II, or VI. In this study people will be randomly&#xD;
      assigned to one of two groups. One group will be treated with adalimumab the first 16 weeks&#xD;
      of the study and then with a saline injection for the last 16 weeks of the study. The other&#xD;
      group will start with the saline injection for 16 weeks and then switch to adalimumab for the&#xD;
      last 16 weeks. The study subject and the study doctor and study coordinator will not know&#xD;
      what group a subject is in until the study is done. Adalimumab is given as an injection, just&#xD;
      under the skin, every 2 weeks. Both groups will have blood drawn at a screening visit, and&#xD;
      then 7 more times over the 32 week study. There will be safety labs done (liver and immune&#xD;
      function tests). Other safety tests include a chest X-ray and screening for tuberculosis&#xD;
      exposure - these will be done at the screening visit and later in the study if there is&#xD;
      concern for tuberculosis exposure or a persistent cough. The following will also be done at&#xD;
      screening, the first, middle, and last study visits: 1) a pregnancy test in all girls 8 and&#xD;
      older, 2) questionnaires that ask about pain, how MPS impacts social and physical function,&#xD;
      and other quality of life questions, 3) height and weight. Finally, a physical exam, that&#xD;
      includes for children and adolescents a check of where they are in puberty, will be done by a&#xD;
      study physician at the first, middle, and last visits. There are risks to taking adalimumab&#xD;
      that include redness and pain where the injection is given, a decreased ability to fight off&#xD;
      infections, and others. The safety tests are designed to identify and decrease the risk&#xD;
      associated with adalimumab. The study physicians believe that the potential benefit of&#xD;
      adalimumab on pain, quality of life, and other MPS related problems outweigh the potential&#xD;
      risks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, pilot study consisting of a 32-week, crossover, double-blind,&#xD;
      placebo-controlled treatment phase of subjects with Mucopolysaccharidosis (MPS) types I, II&#xD;
      or VI treated with enzyme replacement therapy (ERT) and/or hematopoietic cell transplantation&#xD;
      (HCT). Subjects will be treated with adalimumab (group 1) or placebo (group 2) for 16 weeks&#xD;
      (i.e., 8 doses) then cross over to the other group for 16 weeks. Subjects will be treated&#xD;
      with adalimumab (20 mg [weight 15-&lt;30 kg] or 40 mg [weight ≥30 kg] administered&#xD;
      subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other&#xD;
      group for 16 weeks. Laboratory evaluations and Children's Health Questionnaire - Parent Form&#xD;
      50 (CHQ-PF50) for subjects &lt;18 years of age or the Medical Outcomes Study Short Form-36&#xD;
      (SF-36) for subjects ≥18 years will be assessed at Week 16 and 32 to evaluate early treatment&#xD;
      safety and efficacy. Safety will be assessed with laboratory evaluations at 4, 8, 20, and 24&#xD;
      weeks after treatment initiation, and with study visits at week 16 and 32, Physical function&#xD;
      will be measured by the CHQ-PF50/SF-36, joint range of motion (ROM), 6-minute walk test&#xD;
      (6MWT), and strength testing (hand-grip dynamometer) at baseline, 16, and 32 weeks. Joint&#xD;
      inflammation will be measured by serum markers at baseline, 16, and 32 weeks. Anthropometric&#xD;
      measurements will also be performed at Baseline and 16 and 32 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score</measure>
    <time_frame>day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
    <description>Children's Health Questionnaire - Parent Form 50 bodily pain (BP) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean increased pain. The difference of change in BP standardized score from day 0 to week 16 during adalimumab treatment minus change in BP standardized score from day 0 to week 16 during placebo treatment is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Children's Health Questionnaire - Parent Form 50 Physical Function (PF) Standardized Score</measure>
    <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
    <description>Children's Health Questionnaire - Parent Form 50 physical function (PF) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean decreased physical function. The difference of change in PF standardized score from day 0 to week 16 during adalimumab treatment minus change in PF standardized score from day 0 to week 16 during placebo treatment is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Measured by the Visual Analog Scale (VAS) in the Pediatric Pain Questionnaire (PPQ)</measure>
    <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
    <description>Percent of participants with a &gt;10 mm improvement in either &quot;how you feel now&quot; or &quot;worst pain you had this week&quot; on the VA in the PPQ during adalimumab versus during placebo by either parental or subject report. Range is 0-100 mm; lower number means less pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion - Bilateral Shoulder, Elbow, Hip, Knee</measure>
    <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
    <description>Number of joints with a &gt;5 degree more positive change during 16 weeks of adalimumab versus 16 weeks of placebo. A total of eight joints were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-ERT Antibodies</measure>
    <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
    <description>Anti-laronidase antibodies for subjects with MPS I. Anti-idursulfase antibodies for subjects with MPS II.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Mucopolysaccharidosis Type I</condition>
  <condition>Mucopolysaccharidosis Type II</condition>
  <condition>Mucopolysaccharidosis Type VI</condition>
  <arm_group>
    <arm_group_label>Adalimumab first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subjects will be treated with adalimumab (20 mg [weight 15-&lt;30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.</description>
    <arm_group_label>Adalimumab first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline placebo</description>
    <arm_group_label>Adalimumab first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Adalimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MPS I, II or VI;&#xD;
&#xD;
          -  Treatment with ERT for ≥1 year or no ERT for ≥1 year;&#xD;
&#xD;
          -  Weight ≥15 kg;&#xD;
&#xD;
          -  Bodily pain reported by the CHQ-PF50 or SF-36 &gt; 1 SD below the general population&#xD;
             mean;&#xD;
&#xD;
          -  ≥ 3 joints with limitations in motion; and&#xD;
&#xD;
          -  Patient or parent/legal guardian is able and willing to provide informed consent. For&#xD;
             patients 7 to 17 years of age, assent must also be provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of HCT less than 2 years prior to enrollment;&#xD;
&#xD;
          -  Immune suppression therapy less than 1 year prior to enrollment;&#xD;
&#xD;
          -  Active graft versus host disease;&#xD;
&#xD;
          -  Current diagnosis or history of lymphoma or other malignancy;&#xD;
&#xD;
          -  Current active infection;&#xD;
&#xD;
          -  History of serious opportunistic infection (e.g., bacterial [Legionella and Listeria];&#xD;
             tuberculosis [TB]; invasive fungal infections; or viral, parasitic, and other&#xD;
             opportunistic infections);&#xD;
&#xD;
          -  Positive TB skin test, positive chest X-ray, or a recent exposure to TB&#xD;
&#xD;
          -  Congestive heart failure defined by an ejection fracture &lt;50% measured by ECHO;&#xD;
&#xD;
          -  Demyelinating disorders (e.g., central nervous system [CNS] disorders including&#xD;
             multiple sclerosis and optic neuritis and peripheral nervous system disorders&#xD;
             including Guillain-Barre syndrome);&#xD;
&#xD;
          -  Hematologic abnormalities (e.g., pancytopenia, aplastic anemia);&#xD;
&#xD;
          -  Hepatitis B infection (active or chronic carrier);&#xD;
&#xD;
          -  Latex sensitivity;&#xD;
&#xD;
          -  Pregnancy or breastfeeding;&#xD;
&#xD;
          -  Known or suspected allergy to adalimumab or related products;&#xD;
&#xD;
          -  Participation in simultaneous therapeutic study that involves an investigational study&#xD;
             drug or agent within 4 weeks of study enrollment;&#xD;
&#xD;
          -  Requirement for live vaccine exposure that would be expected to occur during the time&#xD;
             frame of the study; or&#xD;
&#xD;
          -  Any other social or medical condition that the Investigator believes would pose a&#xD;
             significant hazard to the subject if the investigational therapy were initiated or be&#xD;
             detrimental to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynda E Polgreen, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>May 3, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Tumor necrosis factor - alpha inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/?term=28119823</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab First, Then Placebo</title>
          <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Adalimumab</title>
          <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab First, Then Placebo</title>
          <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Adalimumab</title>
          <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" lower_limit="15" upper_limit="15"/>
                    <measurement group_id="B2" value="6" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="B3" value="10.5" lower_limit="6" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score</title>
        <description>Children's Health Questionnaire - Parent Form 50 bodily pain (BP) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean increased pain. The difference of change in BP standardized score from day 0 to week 16 during adalimumab treatment minus change in BP standardized score from day 0 to week 16 during placebo treatment is reported.</description>
        <time_frame>day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
        <population>This was a cross-over study so within-individual changes are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab First, Then Placebo</title>
            <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Adalimumab</title>
            <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score</title>
          <description>Children's Health Questionnaire - Parent Form 50 bodily pain (BP) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean increased pain. The difference of change in BP standardized score from day 0 to week 16 during adalimumab treatment minus change in BP standardized score from day 0 to week 16 during placebo treatment is reported.</description>
          <population>This was a cross-over study so within-individual changes are reported.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Children's Health Questionnaire - Parent Form 50 Physical Function (PF) Standardized Score</title>
        <description>Children's Health Questionnaire - Parent Form 50 physical function (PF) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean decreased physical function. The difference of change in PF standardized score from day 0 to week 16 during adalimumab treatment minus change in PF standardized score from day 0 to week 16 during placebo treatment is reported.</description>
        <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab First, Then Placebo</title>
            <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Adalimumab</title>
            <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Children's Health Questionnaire - Parent Form 50 Physical Function (PF) Standardized Score</title>
          <description>Children's Health Questionnaire - Parent Form 50 physical function (PF) standardized score for participants &lt; 18 years of age. Range is from 0 to 100 (no units) and standardization if determined by comparison to healthy age matched children. Lower values mean decreased physical function. The difference of change in PF standardized score from day 0 to week 16 during adalimumab treatment minus change in PF standardized score from day 0 to week 16 during placebo treatment is reported.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.4" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Measured by the Visual Analog Scale (VAS) in the Pediatric Pain Questionnaire (PPQ)</title>
        <description>Percent of participants with a &gt;10 mm improvement in either &quot;how you feel now&quot; or &quot;worst pain you had this week&quot; on the VA in the PPQ during adalimumab versus during placebo by either parental or subject report. Range is 0-100 mm; lower number means less pain.</description>
        <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab First, Then Placebo</title>
            <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Adalimumab</title>
            <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Measured by the Visual Analog Scale (VAS) in the Pediatric Pain Questionnaire (PPQ)</title>
          <description>Percent of participants with a &gt;10 mm improvement in either &quot;how you feel now&quot; or &quot;worst pain you had this week&quot; on the VA in the PPQ during adalimumab versus during placebo by either parental or subject report. Range is 0-100 mm; lower number means less pain.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Range of Motion - Bilateral Shoulder, Elbow, Hip, Knee</title>
        <description>Number of joints with a &gt;5 degree more positive change during 16 weeks of adalimumab versus 16 weeks of placebo. A total of eight joints were measured.</description>
        <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab First, Then Placebo</title>
            <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Adalimumab</title>
            <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Range of Motion - Bilateral Shoulder, Elbow, Hip, Knee</title>
          <description>Number of joints with a &gt;5 degree more positive change during 16 weeks of adalimumab versus 16 weeks of placebo. A total of eight joints were measured.</description>
          <units>joints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-ERT Antibodies</title>
        <description>Anti-laronidase antibodies for subjects with MPS I. Anti-idursulfase antibodies for subjects with MPS II.</description>
        <time_frame>Day 0 to week 16 of treatment with adalimumab versus placebo</time_frame>
        <population>No participants had anti-ERT antibodies</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab First, Then Placebo</title>
            <description>Participants first received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Adalimumab</title>
            <description>Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to &lt;30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-ERT Antibodies</title>
          <description>Anti-laronidase antibodies for subjects with MPS I. Anti-idursulfase antibodies for subjects with MPS II.</description>
          <population>No participants had anti-ERT antibodies</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab</title>
          <description>20 mg subQ every other week (weight 15 to &lt;30 kg) 40 mg subQ every other week (weight ≥30 kg).&#xD;
Adalimumab: Subjects will be treated with adalimumab (20 mg [weight 15-&lt;30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline placebo injection&#xD;
Placebo: Saline placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Resolved by 2 week recheck without intervention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Resolved after 2 days without intervention</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood lability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small pilot study of 2 participants.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lynda Polgreen (PI)</name_or_title>
      <organization>Los Angeles Biomedical Research Institute at Harbor-UCLA</organization>
      <phone>310-222-1961</phone>
      <email>lpolgreen@labiomed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

